A systematic cochrane review of probiotics for people with cystic fibrosis

Coffey, Michael J.; Garg, Millie; Homaira, Nusrat; Jaffé, Adam; Ooi, Chee Y.

doi:10.1016/j.prrv.2020.06.020

Cited by 5 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from individual trials have cited a reduction in in inflammation [16][17][18], nutritional status [19], and pulmonary health outcomes [20,21] (Table 1). From 2016 to 2021, six systematic reviews have attempted to synthesise the expanding evidence for probiotics in CF [15,[197][198][199][200][201]. The first review in 2016 [201] examined a total of nine trials with a total of 275 subjects, and found that probiotics were likely to decrease gut dysbiosis and improve gut maturity and function.…”

Section: Probiotics In Cfmentioning

confidence: 99%

“…Probiotics have reported beneficial effects in diseases with links to a GI dysbiosis, inflammation, and respiratory function [ 15 , 152 , 156 ]. However, knowledge gaps exist related to robust evidence-based probiotic use as a result of the significant heterogeneity between studies and variability in the probiotic strains studied.…”

Section: Microbiome Modulation With Probioticsmentioning

confidence: 99%

“…The use of probiotics in CF has been investigated in 17 clinical trials. Of those 17 trials, 12 were RCTs, with 8 trials including children and 4 trials including both children and adults [ 15 ]. The number of subjects within the RCTs ranged from 22 to 81, and the trial duration ranged from 1 month to 12 months.…”

Section: Microbiome Modulation With Probioticsmentioning

confidence: 99%

“…As public awareness and acceptance of probiotics and prebiotics continue to expand, there is a growing interest in the potential clinical benefits of dietary prebiotics and probiotics in CF. A total of 17 probiotic trials, including 12 RCTs, have thus far investigated the safety and efficacy of individual probiotic strains and strain combinations in children and adults with CF [ 15 ]. Promising improvements in inflammation [ 16 , 17 , 18 ], nutritional status [ 19 ], and health outcomes [ 20 , 21 ] have been observed.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics?

2022

Self Cite

View full text Add to dashboard Cite

Cystic fibrosis (CF) is a life-shortening genetic disorder that affects the cystic fibrosis transmembrane conductance regulator (CFTR) protein. In the gastrointestinal (GI) tract, CFTR dysfunction results in low intestinal pH, thick and inspissated mucus, a lack of endogenous pancreatic enzymes, and reduced motility. These mechanisms, combined with antibiotic therapies, drive GI inflammation and significant alteration of the GI microbiota (dysbiosis). Dysbiosis and inflammation are key factors in systemic inflammation and GI complications including malignancy. The following review examines the potential for probiotic and prebiotic therapies to provide clinical benefits through modulation of the microbiome. Evidence from randomised control trials suggest probiotics are likely to improve GI inflammation and reduce the incidence of CF pulmonary exacerbations. However, the highly variable, low-quality data is a barrier to the implementation of probiotics into routine CF care. Epidemiological studies and clinical trials support the potential of dietary fibre and prebiotic supplements to beneficially modulate the microbiome in gastrointestinal conditions. To date, limited evidence is available on their safety and efficacy in CF. Variable responses to probiotics and prebiotics highlight the need for personalised approaches that consider an individual’s underlying microbiota, diet, and existing medications against the backdrop of the complex nutritional needs in CF.

show abstract

Section: Probiotics In Cfmentioning

confidence: 99%

Section: Microbiome Modulation With Probioticsmentioning

confidence: 99%

Section: Microbiome Modulation With Probioticsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics?

2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several clinical studies have attempted to establish whether diet supplementation of probiotics has a positive effect on lung function and rate of infections and exacerbations in CF. A detailed review of such studies is out of the scope of this article as several recent meta-analyses have widely addressed this specific issue [14,[26][27][28]55]. Although most of the studies are concordant in reporting reduction in respiratory exacerbations in CF patients and improvement of respiratory function following probiotic intake [22,23,[26][27][28][29]56,57], discrepant results of poor or no effect of probiotics supplementation in CF also exist [24,25], leaving the question of the effectiveness of such interventions in CF open.…”

Section: Clinical Studies Of Probiotic Supplementation In Cfmentioning

confidence: 99%

Lung-Directed Bacteriotherapy in Cystic Fibrosis: Could It Be an Option?

et al. 2022

View full text Add to dashboard Cite

Due to the alarming spread of bacterial resistance to conventional drugs, the sole use of antibiotics to fight lung infections in cystic fibrosis (CF) is not resolutive, and novel strategies to replace or complement the use of antibiotics are highly desirable. Among these strategies, the use of probiotics is emerging as a particularly attractive approach. Probiotic administration via the oral route has demonstrated an ability to improve lung function and to reduce infection and exacerbation rates in CF patients through mechanisms mainly attributable to the gut–lung axis. Nevertheless, some studies reported no beneficial effect of probiotic intake suggesting that there is margin for improvement of such innovative intervention in CF. The present review aims to address the rationale behind probiotic use in CF and discuss the hypothesis that nasal/aerosol administration of appropriate probiotic strains may help to exert a direct beneficial effect on the respiratory tract, increasing the effectiveness of probiotic interventions in CF patients.

show abstract

Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy

Lahiri

Sullivan

2021

Pediatric Pulmonology

View full text Add to dashboard Cite

Highly effective modulator therapy (HEMT) for cystic fibrosis (CF) has been touted as one of the greatest advances to date in CF care. As these therapies are now available for many older children and adults with CF, marked improvement of their nutritional status, pulmonary and gastrointestinal symptoms has been observed. However, most infants and younger children are not current candidates for HEMT due to age and/or cystic fibrosis transmembrane conductance regulator (CFTR) mutation. For these young children, it is essential to provide rigorous monitoring and care to avoid potential disease sequelae while awaiting HEMT availability. The following article highlights recent advances in the care of infants and young children with CF with regard to surveillance and treatment of nutritional, pulmonary, and gastrointestinal disorders. Recent clinical trials in this population are also reviewed.

show abstract

A systematic cochrane review of probiotics for people with cystic fibrosis

Cited by 5 publications

References 27 publications

What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics?

What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics?

Lung-Directed Bacteriotherapy in Cystic Fibrosis: Could It Be an Option?

Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy

Contact Info

Product

Resources

About